Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1

Interventions

pembrolizumab 37Carboplatin 31Cisplatin 30Paclitaxel 23Nivolumab 21Pemetrexed 21Dexamethasone 18Gemcitabine 18Ipilimumab 15Docetaxel 13Fluorouracil 13Capecitabine 12Rituximab 12Cyclophosphamide 10Cytarabine 10Trastuzumab 9atezolizumab 9daratumumab 9olaparib 9130-nm albumin-bound paclitaxel 8Lenalidomide 8Prednisone 8durvalumab 8trastuzumab deruxtecan 8Bevacizumab 7Bortezomib 7Fulvestrant 7Oxaliplatin 7Vinorelbine 7cabozantinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Has announcements × ponatinib × Clear all
NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Takeda

Phase 3 Active not recruiting
245 enrolled 15 charts 1 FDA
LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡